Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $224,064.84 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 5,381 shares of the firm’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $41.64, for a total value of $224,064.84. Following the transaction, the director now owns 319,752 shares in the company, valued at approximately $13,314,473.28. This represents a 1.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Pro-Dex Trading Down 0.7 %

Shares of NASDAQ PDEX opened at $42.95 on Friday. Pro-Dex, Inc. has a 1-year low of $16.18 and a 1-year high of $59.60. The business has a fifty day moving average price of $47.59 and a 200 day moving average price of $34.34. The stock has a market capitalization of $140.02 million, a P/E ratio of 27.89 and a beta of 0.56. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.41 and a quick ratio of 1.94.

Pro-Dex (NASDAQ:PDEX) last released its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 EPS for the quarter, beating the consensus estimate of $0.38 by $0.23. Pro-Dex had a net margin of 9.17% and a return on equity of 16.74%. Equities research analysts expect that Pro-Dex, Inc. will post 2 EPS for the current fiscal year.

Hedge Funds Weigh In On Pro-Dex

Several institutional investors and hedge funds have recently bought and sold shares of PDEX. Ritholtz Wealth Management purchased a new stake in shares of Pro-Dex during the 4th quarter valued at $572,000. Dimensional Fund Advisors LP increased its position in Pro-Dex by 5.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock valued at $1,238,000 after buying an additional 3,067 shares in the last quarter. Geode Capital Management LLC increased its position in Pro-Dex by 9.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock valued at $819,000 after buying an additional 2,296 shares in the last quarter. Bard Associates Inc. raised its stake in Pro-Dex by 17.6% in the third quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock valued at $406,000 after buying an additional 2,031 shares during the last quarter. Finally, FMR LLC boosted its holdings in Pro-Dex by 34.9% in the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after acquiring an additional 1,028 shares in the last quarter. 15.28% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on PDEX shares. StockNews.com upgraded shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 14th. Ascendiant Capital Markets lifted their price objective on shares of Pro-Dex from $30.00 to $52.00 and gave the company a “buy” rating in a report on Monday, November 11th.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.